Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines.
Under the terms of the agreement, Precision's proprietary NanoAssemblr™ platform will be used to manufacture GMP batches to support clinical studies and commercial development for RNA medicines developed using Arcturus' proprietary LUNAR™ RNA Therapeutics platform.
James Taylor, Ph.D., CEO of Precision commented, "We are delighted to partner with Arcturus to advance their pipeline of RNA medicines for the treatment of rare diseases. We have been working very closely with Arcturus during the discovery phase of the LUNAR™ products and we are excited to support ongoing development through clinical manufacture using our NanoAssemblr™ microfluidics-based platform for the manufacture of nanomedicines."
Joseph Payne, President and CEO of Arcturus added, "Arcturus is delighted to work with Precision and utilize their NanoAssemblr™ platform to advance our pipeline of RNA medicines. We believe this relationship will accelerate clinical development and enable us to effectively formulate our LUNARTM nanoparticles."
Arcturus Therapeutics, Inc.